Viking Therapeutics Stock Discussion

$Viking Therapeutics (VKTX.US)$
Viking Therapeutics Advances Obesity Drug to Phase 3 with $852M War Chest, Reports Q1 Results

Morning Movers
Gapping Up
$Hertz Global (HTZ.US)$ soared 17.2%, building on the previous session's momentum. On Wednesday, the stock had already jumped over 56% after Bill Ackman's Pershing Square revealed a significant investment in the company.
$Eli Lilly and Co (LLY.US)$ surged 10.8% in Thursday's premarket trading following the company's announcement that its oral GLP-1 receptor agonist, orforglipron, achieved the primary endpoi...

$Viking Therapeutics (VKTX.US)$
Could the failure of Pfizer's obesity pill force the drugmaker to spend billions on an acquisition to break into the blockbuster weight-loss market wide open???? VKTX becomes more appealing now but who says HIMS doesnt swoop in before Pfizer does??? $Hims & Hers Health (HIMS.US)$
following closely in the next 1 to 3 months VKTX will advance as more data is set to release from trials and their stock returns to 40-50 with a buyout in the 120 - 150 ra...

$Viking Therapeutics (VKTX.US)$ Sitting on support.
Should have a mini bounce of 15-20% from here

Here are the levels to watch on this PM move.
$Viking Therapeutics (VKTX.US)$  

$Viking Therapeutics (VKTX.US)$
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint foc...

$Viking Therapeutics (VKTX.US)$
Major Milestone: Viking's Oral Weight Loss Drug Advances with 280-Patient Phase 2 Trial

$Viking Therapeutics (VKTX.US)$
👇🏻🔬🔬🔬🧫🧫🧫💊💊💊🧮🧮🧮🚀🚀🚀
fiercepharma.co...